Dentsply Sirona in the News: Conference Participation and Analyst Ratings

Dentsply Sirona, a leading manufacturer of professional dental products and technologies, continues to evolve its market position. The company's participation in the Stifel Jaws & Paws Conference provided an opportunity to update investors on its strategic initiatives. A live audio webcast and replay were made available on the company's website.

Analyst ratings on DENTSPLY SIRONA Inc. (NASDAQ:XRAY) vary, with a consensus recommendation of "Hold." MarketBeat reports that 14 analysts cover the firm, with three recommending a "Sell," eight a "Hold," and three a "Buy." The average 12-month price target among analysts is $13.82.

Recent analysis includes:

The company reported EPS of $0.27 for the last quarter, slightly below the consensus estimate of $0.28. However, revenue came in at $880 million, exceeding estimates of $841.8 million. The company has guided FY 2026 EPS to $1.40–1.50.

Insider buying activity has increased, with directors Gregory T. Lucier and James D. Forbes purchasing shares. Total insider purchases reached 70,000 shares over the last 90 days. Institutional ownership remains high at 95.7%.

The company is focused on expanding its digital dentistry capabilities, aligning with the industry's shift toward digitized treatment planning, imaging systems, and chairside manufacturing solutions.

XRAY

Hold

$880 million

What are your thoughts on Dentsply Sirona's future prospects in the evolving dental technology market? Share this article with others who need to stay ahead of this trend!